These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15464942)

  • 41. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention.
    Busch G; Steppich B; Sibbing D; Braun SL; Stein A; Groha P; Schömig A; Kastrati A; von Beckerath N; Ott I
    Thromb Haemost; 2009 Feb; 101(2):340-4. PubMed ID: 19190819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bivalirudin.
    Warkentin TE; Greinacher A; Koster A
    Thromb Haemost; 2008 May; 99(5):830-9. PubMed ID: 18449412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exploration of Bivalirudin Use during Percutaneous Coronary Intervention for High Bleeding Risk Patients with Chronic Total Occlusion.
    Li C; Shen Y; Xu R; Dai Y; Chang S; Lu H; Ge L; Ma J; Qian J; Ge J
    Int Heart J; 2018 Mar; 59(2):293-299. PubMed ID: 29563377
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
    Chew DP
    Hamostaseologie; 2002 Aug; 22(3):60-6. PubMed ID: 12215763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Similar success rates with bivalirudin and unfractionated heparin in bare-metal stent implantation.
    Hallak O; Shams SA; Broce M; Lavigne PS; Lucas BD; Elhabyan AK; Reyes BJ
    Cardiovasc Intervent Radiol; 2007; 30(5):906-11. PubMed ID: 17508239
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bivalirudin versus unfractionated heparin for residual thrombus burden: a frequency-domain optical coherence tomography study.
    Vergallo R; Joye R; Barlis P; Jia H; Tian J; Soeda T; Minami Y; Hu S; Dauerman HL; Toma C; Chan J; Lee H; Biasucci LM; Crea F; Jang IK
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):575-82. PubMed ID: 25115992
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Utilisation of bivalirudin and vascular closure devices for same-day discharge after percutaneous coronary and peripheral interventions.
    Szymański RJ; Kiesz RS; Wiernek SŁ; Wiernek B; Kawecki D; Dębiński M; Kondys M; Olszewski R; Szyguła J; Buszman PE
    Kardiol Pol; 2016; 74(6):553-60. PubMed ID: 26620685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical experience with the use of bivalirudin in a large population undergoing endovascular abdominal aortic aneurysm repair.
    Stamler S; Katzen BT; Tsoukas AI; Baum SZ; Diehm N
    J Vasc Interv Radiol; 2009 Jan; 20(1):17-21. PubMed ID: 19026565
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: data from a real-world registry.
    Shammas NW; Shammas GA; Jerin M; Dippel EJ; Shammas AN
    J Endovasc Ther; 2010 Feb; 17(1):31-6. PubMed ID: 20199263
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Post-Procedural Bivalirudin Infusion Following Primary PCI to Reduce Stent Thrombosis.
    Kinnaird T; Yazji K; Thornhill L; Butt M; Ossei-Gerning N; Choudhury A; Mitra R; Anderson R
    J Interv Cardiol; 2016 Apr; 29(2):129-36. PubMed ID: 26822753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Body mass index and bleeding complications after percutaneous coronary intervention: does bivalirudin make a difference?
    Delhaye C; Wakabayashi K; Maluenda G; Belle L; Ben-Dor I; Gonzalez MA; Gaglia MA; Torguson R; Xue Z; Suddath WO; Satler LF; Kent KM; Lindsay J; Pichard AD; Waksman R
    Am Heart J; 2010 Jun; 159(6):1139-46. PubMed ID: 20569731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells.
    Pepke W; Eisenreich A; Jaster M; Ayral Y; Bobbert P; Mayer A; Schultheiss HP; Rauch U
    Cardiovasc Ther; 2013 Apr; 31(2):115-23. PubMed ID: 22212466
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bivalirudin versus unfractionated heparin during peripheral vascular interventions: A Propensity-matched Study.
    Ortiz D; Singh M; Jahangir A; Allaqaband S; Khitha J; Bajwa TK; Mewissen MW
    Catheter Cardiovasc Interv; 2017 Feb; 89(3):408-413. PubMed ID: 27526661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beneficial effects of a point-of-care bleeding risk calculator on anticoagulant selection in the coronary catheterization laboratory.
    Kerl JJ; Spexarth FC; Pedersen R; Stone M; Allaqaband SQ; Schulgit JL; Bajwa TK; Gupta AN; DeFranco AC
    Pharmacotherapy; 2015 Apr; 35(4):388-95. PubMed ID: 25884527
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An objective comparison between bivalirudin and heparin during peripheral vascular interventions.
    Efeovbokhan N; Khouzam RN; Al-Fakhouri A; Salama L
    Future Cardiol; 2014 Nov; 10(6):717-24. PubMed ID: 25495814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions.
    Katzen BT; Ardid MI; MacLean AA; Kovacs MF; Zemel G; Benenati JF; Powell A; Samuels S
    J Vasc Interv Radiol; 2005 Sep; 16(9):1183-7; quiz 1187. PubMed ID: 16151058
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bivalirudin versus heparin as an antithrombotic agent in patients who undergo percutaneous saphenous vein graft intervention with a distal protection device.
    Rha SW; Kuchulakanti PK; Pakala R; Cheneau E; Pinnow E; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Lindsay J; Waksman R
    Am J Cardiol; 2005 Jul; 96(1):67-70. PubMed ID: 15979436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions.
    Allie DE; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Hebert CJ; Ellis SD; Mitran E; Chaisson G; Stagg S; Allie AA; Walker CM
    J Invasive Cardiol; 2003 Jun; 15(6):334-42. PubMed ID: 12777673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
    Sanborn TA; Ebrahimi R; Manoukian SV; McLaurin BT; Cox DA; Feit F; Hamon M; Mehran R; Stone GW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):57-62. PubMed ID: 20118151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.